Reviva Pharmaceuticals Holdings (RVPH) Non Operating Investment Income (2018 - 2020)
Reviva Pharmaceuticals Holdings (RVPH) posted Non Operating Investment Income of $18708.0 for Q1 2020, up 189.62% sequentially from -$20874.0 in Q4 2019, and up 303.08% YoY from $4641.2 in Q1 2019.
Reviva Pharmaceuticals Holdings (RVPH) Non Operating Investment Income (2018 - 2020) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Non Operating Investment Income for 3 years, with the latest figure at $18708.0 in Q1 2020.
- Quarterly Non Operating Investment Income rose 303.08% year-over-year to $18708.0 in Q1 2020, while the trailing twelve-month figure through Nov 2020 was $18708.0 (up 825.4% YoY) and the FY2020 annual result came in at $18708.0, up 825.4% from the prior year.
- Non Operating Investment Income rose to $18708.0 in Q1 2020 per RVPH's latest filing, from -$20874.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $18708.0 in Q1 2020 and troughed at -$20874.0 in Q4 2019.
- A 3-year average of $168.86 and a median of -$4055.0 in 2018 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 511.64% in 2019, down 91.65% in 2019.
- Over 3 years, Non Operating Investment Income stood at -$10892.0 in 2018, then sank by 91.65% to -$20874.0 in 2019, then soared by 189.62% to $18708.0 in 2020.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered $18708.0, -$20874.0, and $16692.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 29, 2020 | 18,708.00 |
| Feb 29, 2020 | 18,708.00 |
| Nov 30, 2019 | -20,874.00 |
| Nov 30, 2019 | -20,874.00 |
| Aug 31, 2019 | 16,692.00 |
| Aug 31, 2019 | 16,692.00 |
| May 31, 2019 | 10,815.00 |
| May 31, 2019 | 10,815.00 |
| Feb 28, 2019 | -9,212.00 |
| Feb 28, 2019 | -9,212.00 |
| Nov 30, 2018 | -10,892.00 |
| Nov 30, 2018 | -10,892.00 |
| Aug 31, 2018 | -4,055.00 |
| Aug 31, 2018 | -4,055.00 |